22:33:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-28 Bokslutskommuniké 2024
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-06-18 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-02-29 Bokslutskommuniké 2023
2023-11-13 Extra Bolagsstämma 2023
2023-10-19 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-04 Ordinarie utdelning ELOS B 0.00 SEK
2023-05-03 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-10-21 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-04 Ordinarie utdelning ELOS B 0.00 SEK
2022-05-03 Årsstämma 2022
2022-04-26 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-05-04 Ordinarie utdelning ELOS B 1.50 SEK
2021-05-03 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-10-20 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-05 Kvartalsrapport 2020-Q1
2020-04-22 Ordinarie utdelning ELOS B 0.00 SEK
2020-04-21 Årsstämma 2020
2020-02-18 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-04-24 Ordinarie utdelning ELOS B 1.00 SEK
2019-04-23 Kvartalsrapport 2019-Q1
2019-04-23 Årsstämma 2019
2019-02-18 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-07-19 Kvartalsrapport 2018-Q2
2018-04-25 Ordinarie utdelning ELOS B 0.00 SEK
2018-04-24 Årsstämma 2018
2018-04-24 Kvartalsrapport 2018-Q1
2018-02-19 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning ELOS B 1.30 SEK
2017-04-26 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-24 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-04-27 Ordinarie utdelning ELOS B 1.00 SEK
2016-04-26 Kvartalsrapport 2016-Q1
2016-04-26 Årsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-04-28 Bonusutdelning ELOS B 1
2015-04-28 Ordinarie utdelning ELOS B 2.00 SEK
2015-04-27 Årsstämma 2015
2015-04-27 Kvartalsrapport 2015-Q1
2015-02-19 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning ELOS B 2.00 SEK
2014-04-29 Kvartalsrapport 2014-Q1
2014-04-29 Årsstämma 2014
2014-02-21 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-21 Kvartalsrapport 2013-Q2
2013-04-26 Ordinarie utdelning ELOS B 1.00 SEK
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-25 Årsstämma 2013
2013-02-22 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-22 Kvartalsrapport 2012-Q2
2012-04-24 Ordinarie utdelning ELOS B 1.50 SEK
2012-04-23 Årsstämma 2012
2012-04-23 Kvartalsrapport 2012-Q1
2012-02-24 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-04 Ordinarie utdelning ELOS B 1.50 SEK
2011-05-03 Kvartalsrapport 2011-Q1
2011-05-03 Årsstämma 2011
2011-02-25 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-29 Ordinarie utdelning ELOS B 0.00 SEK
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-25 Bokslutskommuniké 2009
2009-10-23 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-30 Ordinarie utdelning ELOS B 1.50 SEK
2009-04-29 Årsstämma 1
2009-04-29 Kvartalsrapport 2009-Q1
2008-04-29 Ordinarie utdelning ELOS B 1.50 SEK
2007-04-26 Ordinarie utdelning ELOS B 0.50 SEK
2006-04-28 Ordinarie utdelning ELOS B 1.25 SEK
2005-05-20 Split ELOS B 1:2
2005-05-04 Ordinarie utdelning ELOS B 2.50 SEK
2004-04-30 Ordinarie utdelning ELOS B 0.00 SEK
2003-05-07 Ordinarie utdelning ELOS B 0.00 SEK
2002-04-26 Ordinarie utdelning ELOS B 0.00 SEK
2001-04-27 Ordinarie utdelning ELOS B 2.25 SEK
1995-06-15 Split ELOS B 1:2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Elos Medtech är verksamt inom medicinteknik. Bolaget arbetar med forskning och utveckling av produkter och medicintekniska komponenter för dentala- och ortopediska implantat. Verksamheten bedrivs via egna anläggningar runtom Norden, Nordamerika och Asien. Kunderna utgörs huvudsakligen av internationellt verksamma företagskunder. Huvudkontoret ligger i Göteborg.
2021-10-20 08:00:00

GOOD DEVELOPMENT IN ALL BUSINESS AREAS

July - September 2021
  • Net sales for the third quarter amounted to SEK 187.2 (147.9) million, an increase of 26.6 percent compared to the same period last year. Net sales in local currencies increased by 27.1 percent.
  • Operating profit for the year was SEK 24.2 (17.9) million, corresponding to an operating margin of 12.9 (12.1) percent. In the third quarter of last year government grant and subsidies due to Covid-19 had a positive impact of SEK 4.4 million on operating profit.
  • Operating profit includes a charge of SEK 11.8 million related to transaction costs in connection with the completion of the offer from the new majority owner.
  • Profit after net financial items amounted to SEK 23.3 (14.2) million. Exchange rate differences and revaluation of interest rate swaps had a positive impact on net financial items of SEK 1.1 (-1.3) million and SEK 0.4 (0.4) million, respectively, resulting in a net financial loss of SEK -1.0 (-3.7) million.
  • Profit after tax amounted to SEK 17.6 (12.6) million.
  • Cash flow from operating activities was SEK 12.9 (41.9) million, amounting to SEK 1.5 (32.2) million after investments.
  • Earnings per share amounted to SEK 2.18 (1.56).

CEO JAN WAHLSTRÖM COMMENTS ON Q3

The third quarter developed well and sales growth for the quarter was 27 percent compared to a covid-affected weak quarter in 2020. All business areas reported strong sales and earnings. The operating profit is in line with last year's figure and meets our long-term target of 13 percent.

In Dental we are seeing a solid development in contract manufacturing as well as proprietary products. The introduction of Elos Accurate® Hybrid Base H™ with a higher cylinder, the latest member of our digital product portfolio, was well received in the United States.

In Life Science we achieved a good quarter in terms of both sales and earnings. The performance was partly a result of inventory effects. We have also noted a recovery among customers who for a long time have been affected by the pandemic.

The growth in Orthopedics has remained and the business area is operating at a high pace. However, restoring a balance in recruitment in the US will continue to pose a challenge as will strengthening our pool of engineering and technical expertise globally. Organizationally, we are still operating with a relatively slim organization.

As the world begins to return to what we view as normal we are doing the same. We have participated with proprietary products at dental trade fairs in the US and Germany and at an orthopedics fair in the US. Yet in the so-called `new normal' we are also seeing tendencies toward a higher cost environment going forward that is primarily due to macroeconomic factors such as inflation and higher raw material prices.

With TA Associates as our new majority owner and a new Board in place, we are entering the next chapter in Elos Medtech's journey. We would like to express our gratitude to the previous Board of Directors and will continue to pursue our adopted goal - to sustainably grow faster than the market. In order to secure our long-term growth in line with our strategic business plan, we are now investing in both machinery and technical solutions as well as in the skills of our highly valued employees. We are doing this with strong confidence and commitment with the aim of meeting our customers' future needs for specialized capacity and skills.